Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Abbott Laboratories Trading Volume Drops 22.53% Ranking 42nd Amid Stock Price Surge

Market BriefThursday, Apr 17, 2025 7:51 pm ET

1min read

Abbott Laboratories reported a trading volume of $1.372 billion on April 17, 2025, marking a 22.53% decrease from the previous day. The company's trading volume ranked 42nd among all stocks traded that day. Abbott's stock price has been on an upward trend, rising 0.99% and marking two consecutive days of gains, with a total increase of 3.77% over the past two days.

Abbott Laboratories has announced that it will be hosting a conference call to discuss its first-quarter 2025 financial results. The call is scheduled for April 24, 2025, at 8:30 AM Eastern Time. During the call, the company's management team will provide an overview of the company's financial performance for the quarter, as well as discuss its outlook for the remainder of the year.

Abbott Laboratories has received approval from the U.S. Food and Drug Administration (FDA) for its new FreeStyle Libre 3 system. The system is a continuous glucose monitoring device that is designed to help people with diabetes manage their blood sugar levels more effectively. The approval is expected to drive sales growth for the company in the coming quarters.

Abbott Laboratories has announced that it will be acquiring Alere, a leading provider of rapid diagnostic tests, for $5.8 billion. The acquisition is expected to strengthen Abbott's position in the diagnostic testing market and drive growth in the company's medical devices segment. The deal is expected to close in the second half of 2025, subject to regulatory approval.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.